Purification of intravenous immunoglobulin G from human plasma - Aspects of yield and virus safety

Biotechnology Journal

Volumn 1, Issue 2, 2006, Pages 148-163

  Buchacher, Andrea ^a   Iberer, Günter ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

IVIG; Virus safety; Yield

Indexed keywords

BLOOD PRODUCTS; ETHANOL FRACTIONATION; HIGH YIELD; HUMAN PLASMAS; IMMUNOGLOBULIN G; INFECTIOUS DISEASE; INFLAMMATORY DISEASE; ISOLATION AND PURIFICATION; IVIG; LOGARITHMIC REDUCTION; MANUFACTURING PROCESS; PLASMA FRACTIONATION; PLASMA PRODUCTS; SECONDARY ANTIBODIES; VIRUS INACTIVATION; VIRUS REMOVAL; YIELD;

ANTIBODIES; ETHANOL; PLASMAS; PURIFICATION; VIRUSES;

ACCIDENT PREVENTION;

IMMUNOGLOBULIN;

BLOOD; FRACTIONATION; HUMAN; INSTRUMENT STERILIZATION; ISOLATION AND PURIFICATION; LIQUID CHROMATOGRAPHY; METHODOLOGY; REVIEW; SAFETY; VIROLOGY; VIRUS; VIRUS INACTIVATION;

BLOOD; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, LIQUID; CONSUMER PRODUCT SAFETY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; STERILIZATION; VIRUS INACTIVATION; VIRUSES;

EID: 33749253824     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200500037     Document Type: Review

References (118)

1. Beeck, H., Hellstern, P., In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 1998, 74, 219-223.
2. Dickler, H.B., Gelfand, E.W., Current perspectives on the use of intravenous immunoglobulin. Adv. Intern. Med. 1996, 41, 641-680.
3. Stiehm, E.R., Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr. Infect. Dis. J. 1997, 16, 696-707.
4. Schiff, R.I., Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr. Allerg. Immunol. 1994, 5, 63-87.
5. Knezevic-Maramica, I., Kruskall, M.S., Intravenous immune globulins: an update for clinicans. Transfusion 2003, 43, 1460-1480.
6. Lemieux, R., Bazin, R., Néron, S., Therapeutic intravenous immunoglobulins. Mol. Immunol. 2005, 42, 839-848.
7. Curling, J.M. (Ed.), Methods of Plasma Protein Fractionation, Academic Press Inc., 1980
8. The Plasma Protein Therapeutics Association Website: http://www. pptagglobal.org [24 October 2005]
9. The Marketing Research Bureau, I., The worldwide plasma fractions market 2004. February 2005, 38-44.
10. Humphreys, D.P., Glover, D.J., Therapeutic antibody production technologies: Molecules, applications, expression and purification. Curr. Opin. Drug Discov. Devel. 2001, 4, 172-185.
11. Humphreys, D.P., Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification. Curr. Opin. Drug Discov. Devel. 2003, 6, 188-196.
12. Sharon, J., Sompuram, S.R., Yang, C.-Y., Williams, B.R., Sarantopoulos, S., Construction of polyclonal antibody libraries using phage display, in: O'Brien, P.M., Aitken, R. (Ed.), Methods in Molecular Biology. Humana Press Inc., Totowa, NJ 2002, 101-112.
13. Bregenholt, S., Haurum, J., Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin. Biol. Ther. 2004, 4, 387-396.
14. Haurum, J., Bregenholt, S., Recombinant polyclonal antibodies: Therapeutic antibody technologies come full circle. Drugs 2005, 8, 404-409.
15. Rasmussen, L.K., Berger Larsen, Y., Hojrup, P., Characterization of different cell culture media for expression of recombinant antibodies in mammalian cells: Presence of contaminating bovine antibodies. Protein Express Purif. 2005, 41, 373-377.
16. Green, A.A., Hughes, W.L., Protein fractionation on the basis of solubility in aqueous solutions of salts and organic solvents, in: Colowick, S.P., Kaplan, N.O. (Ed.), Methods in Enzymology. Academic Press Inc., New York 1955, pp. 67-90.
17. Cohn, E.J., Strong, L.E., Hughes, W.L., Mulford, D.J., Ashworth, J.N., Melin, M., Taylor, H.L., Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 1946, 68, 459-475.
18. Deutsch, H.F., Gösting, I.J., Alberty, R.A., Williams, J.W., Biophysical studies of blood plasma proteins. J. Biol. Chem. 1946, 164, 109-118.
19. Oncley, J.L., Melin, M., Richert, D.A., Cameron, J.W., Gross, P.M., The separation of the antibodies, isoagglutinins, prothrombin, plas-minogen and ß1-lipoprotein into subfractions of human plasma. J. Am. Chem. Soc. 1949, 71, 541-550.
20. Cohn, E.J., Gurd, F.R.N., Surgenor, D.M., Barnes, B.A., Brown, R.K., Derouaux, G., Gillespie, J.M., et al., A system for the separation of the components of human blood: Quantitative procedures for the separation of the protein components of human plasma. J. Am. Chem. Soc. 1950, 72, 465-474.
21. Kistler, P., Nitschmann, H.S., Large scale production of human plasma fractions. Vox Sang. 1962, 7, 414-424.
22. Chanutin, A., Curnish, R.R., The precipitation of plasma proteins by short-chain fatty acids. Arch. Biochem. Biophys. 1960, 89, 218-220.
23. Steinbuch, M., Audran, R., The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch. Biochem. Biophys. 1969, 134, 279-284.
24. Habeeb, A.F.S.A., Francis, R.D., Preparation of human immunoglobulin by caprylic acid precipitation. Prep. Biochem. 1984, 14, 1-17.
25. Lebing, W., Remington, K.M., Schreiner, C., Paul, H.I., Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang. 2003, 84, 193-201.
26. Trejo, S., Hotta, J., Lebing, W., Stenland, C., Storms, R., Lee, D.C., Li, H., et al., Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang. 2003, 84, 176-187.
27. Kothe, N., Rudnick, D., Piechaczek, D., Klein, H., Rohm, D., Kloft, M., Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates. 1995, EP 0 447 585 B1.
28. Parkkinen, J., Process for the manufacture of virus safe immunoglobulin. 2005, WO 2005/073252 A1.
29. Uemura, Y., Yang, Y.H.J., Heldebrant, C.M., Takechi, K., Yokoyama, K., Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang. 1994, 67, 246-254.
30. Uemura, Y., Uriyu, K., Takechi, K., Hirao, Y., Suyama, T., Method of producing immunoglobulin preparations for intravenous injection. 1987, EP 0 246 579 A2.
31. Polson, A., Ruiz-Bravo, C., Fractionation of plasma with polyethylene glycol. Vox Sang. 1972, 23, 107-118.
32. Falksveden, L.G.A., Method for fractionating plasma proteins using PEG and Ion-Exchangers. 1975, US 3,869,436.
33. Uemura, Y., Uriyu, K., Hirao, Y., Takechi, K., Ishikawa, H., Nakajima, T., Kagitani, Y., et al., Inactivation and elimination of viruses during the fractionation of an intravenous immunoglobulin preparation: liquid heat treatment and polyethylene glycol fractionation. Vox Sang. 1989, 56, 155-161.
34. Hirao, Y., Hashimoto, M., Kitamura, T., Uemura, Y., Room temperature storable immunoglobulin preparation for intravenous injection. 1999, EP 0 911 037 B1.
35. Ahrer, K., Buchacher, A., Iberer, G., Josic, D., Jungbauer, A., Analysis of aggregates of human immunoglobulin G using size-exclusion chromatography, static and dynamic light scattering. J. Chromatogr. A 2003, 1009, 89-96.
36. Baumstark, J.S., Laffin, R.J., Bardawil, W.A., A preparative method for the separation of 7S gamma globulin from human serum. Arch. Biochem. Biophys. 1964, 108, 514-522.
37. Hoppe, H., Mester, T., Hennig, W., Krebs, H., Prevention of Rh-immunization. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography (IEC). Vox Sang. 1973, 25, 308-316.
38. Cunningham, C.J., Production of human immunoglobulin anti-D (Rh0) for intravenous administration, for a national Rh prophylaxis programme. Biochemical Society Transactions 1980, 586th Meeting, Bristol, 178-179.
39. Friesen, A.D., Bowman, J.M., Price, H.W., Column ion-exchange preparation and characterization of an Rh immune globulin (Win-Rho) for intravenous use. J. Appl. Biochem. 1981, 3, 164-175.
40. Friesen, A.D., Bowman, J.M., Bees, W.C.H., Column ion exchange chromatographic production of human immune serum globulin for intravenous use. Vox Sang. 1985, 48, 201-212.
41. Bertolini, J., Davies, J., Wu, J., Coppola, G., Purification of immunoglobulins. 1998, WO 98/05686.
42. Friesen, A., Process for preparing purified immune globulin (IgG). 1986, CA 1 201 063.
43. Burnouf-Radosevich, M., Dernis, D., Bonneel, P., Burnouf, T., Immunoglobulin G concentrate for therapeutic use and process for producing said concentrate. 1994, WO 94/29334.
44. Lontos, J., Chromatographic purification of immunoglobulins at CSL bioplasma; A manufacturing perspective. Presentation at the Plasma Product Biotechnology Meeting, Porto Elounda, Crete: http://www.bo-conf.com/ppb05/present/ppt.htm 2005.
45. Laursen, I., Teisner, B., Process for producing immunoglobulins for intravenous administration and other immunoglobulin products. 1999, WO 99/64462.
46. Staby, A., Sand, M.B., Hansen, R.G., Jacobsen, J.H., Andersen, L.A., Gerstenberg, M., Bruus, U.K., et al., Comparison of chromatographic ion-exchange resins (III. Strong cation-exchange resins). J. Chromatogr. A 2004, 1034, 85-97.
47. Burton, S.C., Harding, D.R.K., Hydrophobic charge induction chromatography: salt independent protein adsorption and facile elution with aqueous buffers. J. Chromatogr. A 1998, 814, 71-81.
48. Guerrier, L., Girot, P., Schwartz, W., Boschetti, E., New method for the selective capture of antibodies under physiological conditions. Bioseparation 2000, 9, 211-221.
49. Schwartz, W., Judd, D., Wysocki, M., Guerrier, L., Birck-Wilson, E., Boschetti, E., Comparison of hydrophobic charge induction chromatography with affinity chromatography on protein A for harvest and purification of antibodies. J. Chromatogr. A 2001, 908, 251-263.
50. Hahn, R., Schlegel, R., Jungbauer, A., Comparison of protein A affinity sorbents. J. Chromatogr. B 2003, 790, 35-51.
51. Teng, S.F., Sproule, K., Husain, A., Lowe, C.R., Affinity chromatography on immobilized "biomimetic" ligands synthesis, immobilization and chromatographic assessment of an immunoglobulin Gbinding ligand. J. Chromatogr. B 2000, 740, 1-15.
52. Tankersley, D.L., Preston, S.M., Finlayson, J.S., Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol. Immunol. 1988, 25, 41-48.
53. Miescher, S.M., Schaub, A., Ghielmetti, M., Baumann, M., Vogel, M., Bolli, R., Stadler, B., Comparative analysis of antigen specifities in the monomeric and dimeric fractions of intravenous immunoglobulin. Ann. N.Y. Acad. Sci. 2005, 1051, 582-590.
54. Iberer, G., Schwinn, H., Josic, D., Jungbauer, A., Buchacher, A., Improved performance of protein separation by continuous annular chromatography in the size-exclusion mode. J. Chromatogr. A 2001, 921, 15-24.
55. Tanaka, K., Sawatani, E., Dias, G.A., Shigueoka, E.M., Campos, T.C.X.B., Nakao, H.C., Arashiro, F., High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography. Braz. J. Med. Biol. Res. 2000, 33, 27-30.
56. Buchacher, A., Iberer, G., Jungbauer, A., Schwinn, H., Josic, D., Continuous removal of protein aggregates by annular chromatography. Biotechnol. Prog. 2001, 17, 140-149.
57. Canak, Y., Özkara, S., Akgöl, S., Denizil, A., Pseudo-specific bioaffinity chromatography of immunoglobulin-G. React. Funct. Polym. 2004, 61, 369-377.
58. Curling, J., Baines, D., Bryant, C., Carbonell, R., Chen, T., Gurgel, P., Hayes, T., A comparative study of cohn and chromatographic fractionation using a novel affinity "Cascade Process", Presentation at the Plasma Product Biotechnology Meeting, Porto Elounda, Crete: http://www.bo-conf.com/ppb05/present/ppt.htm 2005.
59. Li, G., Stewart, R., Conlan, B., Gilbert, A., Roeth, P., Nair, H., Purification of human immunoglobulin G: a new approach to plasma fractionation. Vox Sang. 2002, 83, 332-338.
60. Evtushenko, M., Wang, K., Stokes, H.W., Nair, H., Blood protein purification and simultaneous removal of nonenveloped viruses using tangential-flow preparative electrophoresis. Electrophoresis 2005, 26, 28-34.
61. Suomela, H., Inactivation of viruses in blood and plasma products. Transfus. Med. Rev. 1993, II, No 1, 42-57.
62. The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party, Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses. 1996, CPMP/BWP/268/95 http://www.emea.eu.int.html 14 February 1996.
63. Walter, J.K., Nothelfer, F., Werz, W., Validation of viral safety for pharmaceutical proteins, in: Subramanian, G. (Ed.), Bioseparation and Bioprocessing. Wiley-VCH Verlag GmbH, Weinheim, Germany 1998, pp. 465-493.
64. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Topic Q5A Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 1997, Step 5 http://www.ich.org March 1997.
65. Horowitz, B., Lazo, A., Grossberg, H., Page, G., Lippin, A., Swan, G., Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang. 1998, 74, 203-206.
66. Neurath, A.R., Horowitz, B., Undenatured virus-free biologically active protein derivatives. 1985, EP 0 131 740 A2.
67. Woods, K.R., Orme, T.W., Removal of lipid soluble process chemicals from biological materials from biological materials by extraction with naturally occuring oils or synthetic substitutes thereof. 1987, EP 0 239 859 B1.
68. Bonomo, R., Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography. 1992, US 5,094,960.
69. Guerrier, L., Flayeux, I., Boschetti, E., Radosevich, M., Specific sorbent to remove solvent-detergent mixtures from virus-inactivated biological fluids. J. Chromatogr. B 1995, 664, 119-125.
70. Biesert, L., Virus validation studies of immunoglobulin preparations. Clin. Exp. Rheumatol. 1996, 14, 47-52.
71. Lundblad, J., Seng, Inactivation of lipid-enveloped viruses in proteins by caprylate. Vox Sang. 1991, 60, 75-81.
72. Dichtelmüller, H., Rudnick, D., Kloft, M., Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution. Biologicals 2002, 30, 135-142.
73. Korneyeva, M., Hotta, J., Lebing, W., Rosenthal, R.S., Franks, L., Petteway, S.R., Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002, 30, 153-162.
74. Uemura, Y., Uriyu, K., Takechi, K., Hirao, Y., Suyama, T., Method of producing immunoglobulin preparations for intravenous injection. 1992, EP 5132406.
75. Vermeer, A.W.P., Bremer, M.G.E.G., Norde, W., Structural changes of IgG induced by heat treatment and by adsorption onto a hydrophobic Teflon surface studied by circular dichroism spectroscopy. Biochim. Biophy. Acta 1998, 1425, 1-12.
76. Blümel, J., Schmidt, I., Willkommen, H., Löwer, J., Inactivation of Parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002, 42, 1011-1018
77. Yunoki, M., Urayama, T., Tsujikawa, M., Sasaki, Y., Abe, S., Takechi, K., Ikuta, K., Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations. British Journal of Haematology 2004, 128, 401-404.
78. Hayakawa, F., Imada, K., Towatari, M., Saito, H., Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br. J. Haematol. 2002, 118, 1187-1189.
79. Gunn, A., Cameron, I.D., Pepper, D.S., MacDonald, S.L., Li, Q., Device for treatment of biological fluids. 2003, US 6,586,172 B1.
80. Wang, J., Virus inactivation and protein recovery in a novel ultaviolet-C reactor. Vox Sang. 2004, 86, 230-238.
81. Hart, H., Reid, K., Hart, W., Inacitvation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin. Vox Sang. 1993, 64, 82-88.
82. Chin, S., Jin, R., Wang, X.L., Hamman, J., Marx, G., Mou, X., Andersson, I., et al., Virucidal treatment of blood protein products with UVC radiation. Photochem. Photobiol. 1997, 65, 432-435.
83. Schmidt, S., Mora, J., Dolan, S., Kauling, J., An integrated concept for robust and efficient virus clearance and contaminant removal in biotech processes. BioProcess International 2005, 3, 26-31.
84. Caillet-Fauquet, P., Di Giambattista, M., Draps, M.L., Sandras, F., Branckaert, T., de Launoit, Y., Laub, R., Continuous-flow UVC irradiation: a new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19. J. Virol. Methods 2004, 118, 131-139.
85. Burnouf, T., Radosevich, M., Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003, 9, 24-37.
86. Troccoli, N.M., McIver, J., Losikoff, A., Poiley, J., Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998, 26, 321-329.
87. Van Holten, R., Ciavarella, D., Oulundsen, G., Harmon, F., Riester, S., Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process. Vox Sang. 2002, 83, 227-233.
88. Eibl, J., Barrett, N., Hämmerle, T., Dorner, F., Nanofiltration of Immunoglobulin with 35-nm Filters, Fails to Remove Substantial Amounts of HCV. Biologicals 1996, 24, 285-287.
89. Hong, F., Ruiz, R., Price, H., Griffiths, A., Malinoski, F., Woloski, M., Safety profile of WinRho anti-D. Sem. Hematol. 1998, 35, 9-13.
90. O'Grady, J., Lisikoff, A., Poiley, J., Fickett, D., Oliver, C., Virus Removal Studies Using Nanofiltration Membranes. Dev. Biol. Stand. 1996, 88, 319-326.
91. Omar, A., Kempf, C., Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002, 42, 1005-1010.
92. Yokoyama, T., Murai, K., Wakisaka, A., Tanifuji, M., Fujii, N., Tomono, T., Removal of small non-enveloped viruses by nanofiltration. Vox Sang. 2004, 86, 225-229.
93. Tateishi, J., Kitamoto, T., Mohri, S., Satoh, S., Sato, T., Shepherd, A., Macnaughton, M.R., Scrapie removal using Planova virus removal filters. Biologicals 2001, 29, 17-25.
94. Van Holten, R.W., Autenrieth, S., Boose, J.A., Hsieh, W.T., Dolan, S., Removal of prion challenge from an immune globulin preparation by use of size-exclusion filter. Transfusion 2002, 42, 999-1004.
95. Kim, I.S., Yong, W.C., Sung, R.L., Hang, B.C., Ho, G.E., Han, S.W., Chong, E.C., et al., Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation. J. Microbiol. Biotechnol. 2001, 11, 619-627.
96. Henin, Y., Marechal, V., Barre-Sinoussi, F., Chermann, J.C., Morgenthal, J.J., Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sang. 1988, 54, 78-83.
97. Louie, R.E., Galloway, C.J., Dumas, M.L., Wong, M.F., Mitra, G., Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994, 22, 13-19.
98. Lee, D.C., Stenland, C.J., Miller, J.L.C., Cai, K., Ford, E.K., Gilligan, K.J., Hartwell, R.C., et al., A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001, 41, 449-455.
99. Reichl, H.E., Foster, P.R., Welch, A.G., Li, Q., MacGregor, I.R., Somerville, R.A., Fernie, K., et al., Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang. 2002, 83, 137-147.
100. Foster, P.R., Welch, A.G., McLean, C., Griffin, B.D., Hardy, J.C., Bartley, A., MacDonald, S., et al., Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang. 2000, 78, 86-95.
101. Foster, P.R., Removal of TSE agents from blood products. Vox Sang. 2004, 87, 7-10.
102. Hamamoto, Y., Harada, S., Yamamoto, N., Uemura, Y., Goto, T., Suyama, T., Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and sindbis viruses) from an intravenous immunoglobulin preparation. Vox Sang. 1987, 53, 65-69.
103. Morgenthaler, J.J., Lerch, P.G., Virus-safety of immunoglobulin preparations. Biotechnology of plasma proteins 1989, 175, 439-446.
104. Uemura, Y., Dissociation of aggregated IgG and denaturation of monomeric IgG by acid treatment. Tohoku J. Exp. Med. 1983, 141, 337-349.
105. Bos, O., Sunyé, D., Nieuweboer, C., van Engelenburg, F., Schuitemaker, H., Over, J., Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Biologicals 1998, 26, 267-276.
106. Hämäläinen, E., Suomela, H., Ukkonen, P., Virus inactivation during intravenous immunoglobulin production. Vox Sang. 1992, 63, 6-11.
107. Djoumerska, I., Tchorbanov, A., Pashov, A., Vassilev, T., The autoreactivity of therapeutic intravenous immunoglobulin (IVIg) preparations depends on the fraction methods used. Scand. J. Immunol. 2005, 61, 357-363.
108. Zolton, R.P., Padvelskis, J.V., Kaplan, P.M., Removal of hepatitis B virus infectivity from human gamma-globulin prepared by ion-exchange chromatography. Vox Sang. 1985, 49, 381-389.
109. Bees, W.C.H., Friesen, A.D., Janzen, R.G., Validation of a large scale column chromatographic process for production of Albumin and Intravenous Immune Globulin, in: Stoltz, F.J., Rivet, C. (Ed.), Biotechnology of plasma proteins. Inserm, Paris 1989, pp. 207-216.
110. Curtis, S., Lee, K., Blank, G.S., Brorson, K., Xu, Y., Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotech. Bioeng. 2003, 84, 179-186.
111. Norling, L., Lute, S., Emery, R., Khuu, W., Voisard, M., Xu, Y., Chen, Q., et al., Impact of multiple re-use of anion-exchange chromatography media on virus removal. J. Chromatogr. A 2005, 1069, 79-89.
112. Siegel, J., The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005, 25, 78-84.
113. Nydegger, U.E., Sturzenegger, M., Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999, 21, 171-185.
114. Pierce, L.R., Jain, N., Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. 2003, 17, 241-251.
115. Ahrer, K., Buchacher, A., Iberer, G., Jungbauer, A., Detection of aggregate formation during production of human immunoglobulin G by means of light scattering. J. Chromatogr. A 2004, 1043, 41-46.
116. Ahrer, K., Buchacher, A., Iberer, G., Jungbauer, A., Effects of ultra-/diafiltration conditions on present aggregates in human immunoglobulin G preparations. J. Membr. Sci. 2005. in press
117. Farrugia, A., Poulis, P., Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus. Med. 2001, 11, 63-74.
118. Lebing, W.R., Alred, P., Lee, D.C., Paul, H.-I., Chromatographic method for high yield purification and viral inactivation of antibodies. 1999, US 5, 886, 154.